Kera Capital Partners Inc. Makes New Investment in 10x Genomics $TXG

Key Points

• Kera Capital Partners Inc. has acquired 31,018 shares of 10x Genomics, valued at approximately $359,000, during the 2nd quarter, as per their latest SEC filing.
• 10x Genomics reported earnings of $0.28 per share for the last quarter, exceeding the consensus estimate of ($0.35), along with a revenue of $172.91 million, up 12.9% year-over-year.
• Several research analysts have recently downgraded their ratings on 10x Genomics, with the average rating now at "Hold" and a consensus price target of $13.65.

Kera Capital Partners Inc. bought a new stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 31,018 shares of the company's stock, valued at approximately $359,000.

Several other large investors also recently made changes to their positions in TXG. GF Fund Management CO. LTD. acquired a new position in shares of 10x Genomics during the 4th quarter valued at about $32,000. GAMMA Investing LLC boosted its position in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after purchasing an additional 1,614 shares during the period. Signaturefd LLC grew its holdings in 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after purchasing an additional 2,409 shares during the last quarter. Whittier Trust Co. bought a new position in shares of 10x Genomics in the first quarter valued at approximately $41,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock worth $45,000 after buying an additional 3,119 shares during the last quarter. Institutional investors own 84.68% of the company's stock.

10x Genomics Stock Down 3.2%

Shares of TXG opened at $12.64 on Friday. The stock's 50-day moving average price is $13.21 and its 200 day moving average price is $10.81. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -18.06 and a beta of 2.00. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.10x Genomics's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Equities research analysts expect that 10x Genomics will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of 10x Genomics in a research note on Thursday. They issued a "neutral" rating and a $15.00 target price on the stock. Zacks Research downgraded 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 5th. Morgan Stanley cut their price objective on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Tuesday, August 12th. Wall Street Zen downgraded 10x Genomics from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, UBS Group lifted their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $13.65.

Insider Buying and Selling at 10x Genomics

In related news, CEO Serge Saxonov sold 9,348 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the sale, the chief executive officer owned 945,892 shares of the company's stock, valued at $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares of the company's stock, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,149 shares of company stock valued at $539,865 in the last 90 days. 9.39% of the stock is currently owned by company insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.